Login to Your Account



Hard-core success in DLBCL

What Juno: Out of ASHes CAR T therapy on the rise, may 'Transcend' to leader

By Randy Osborne
Staff Writer

Wednesday, November 1, 2017

Juno Therapeutics Inc. "invested to learn deeply" from last year's deaths in clinical trials, Sunil Agarwal, president of research and development, told BioWorld, and "having put both feet in at the beginning" is what led to the success with a chimeric antigen receptor (CAR) T-cell therapy disclosed Wednesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription